Clinical Trial Update: A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

This document describes an EARLY_PHASE1 clinical trial evaluating LVIVO-TaVec200 for relapsed/refractory multiple myeloma, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LVIVO-TaVec200

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING